Zydus Gets USFDA Approval for Duchenne Muscular Dystrophy Drug

The United States Food and Drug Administration (USFDA) has given Zydus Lifesciences final approval to produce medications called Jaythari (Deflazacort).

“Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older,” the pharma company said.

According to a regulatory filing by Zydus, the pharmaceutical company will manufacture Jaythari (Deflazacort) 6 mg, 18 mg, 30 mg, and 36 mg tablets in Doppel Farmaceutici S.r.l., Italy.As of March 31, 2025, the company has submitted 492 ASDAs and received 424 approvals.

Zydus Lifesciences also disclosed to the stock exchanges that, through its fully owned subsidiary Zydus MedTech Private Ltd, it has established a step-down company, Zydus MedTech (France) SAS. For 256.8 million euros, the pharmaceutical company announced on March 11 that it had purchased the majority of 85.6% equity shares in Amplitude Surgical SA, France.

Zydus will give the newly created Zydus MedTech (France) SAS the equity interests of Amplitude Surgical SA, according to the regulatory filing.

Zydus Lifesciences' stock ended the day up 2.90% on the National Stock Exchange (NSE) at ?868.85 per share. The stock dropped 1.98% since the start of April, although it gained 0.22% over the week. The stock has dropped 10.58% so far this year. As on April 12, 2025, Zydus Lifesciences's entire market capitalization on the NSE was ?87,265.64 crore.